22 October 2024 in Nature Communications
Neoadjuvant immunochemotherapy (nICT) has dramatically changed the treatment landscape of operable esophageal squamous cell carcinoma (ESCC), but factors influencing tumor response to nICT are not well understood. Here, using single-cell RNA sequencing paired with T cell receptor sequencing, we profile tissues from ESCC patients accepting nICT treatment and characterize the tumor microenvironment context. CXCL13+CD8+ Tex cells, a subset of exhausted CD8+ T cells, are revealed to highly infiltrate in pre-treatment tumors and show prominent progenitor exhaustion phenotype in post-treatment samples from responders. We validate CXCL13+CD8+ Tex cells as a predictor of improved response to nICT and reveal CXCL13 to potentiate anti-PD-1 efficacy in vivo. Post-treatment tumors from non-responders are enriched for CXCL13+CD8+ Tex cells with notably remarkable exhaustion phenotype and TNFRSF4+CD4+ Tregs with activated immunosuppressive function and a significant clone expansion. Several critical markers for therapeutic resistance are also identified, including LRRC15+ fibroblasts and SPP1+ macrophages, which may recruit Tregs to form an immunosuppressive landscape. Overall, our findings unravel immune features of distinct therapeutic response to nICT treatment, providing a rationale for optimizing individualized neoadjuvant strategy in ESCC.
27 January 2026 in Cancer Research
Cancer-associated fibroblasts (CAF) play a crucial role in shaping the tumor microenvironment and driving tumor progression. Although single-cell transcriptomics has revealed the phenotypic and functional heterogeneity of CAFs, effective therapeutic strategies targeting CAFs remain urgently needed. In this study, we identified LRRC15+ CAFs as a tumor-specific CAF subset in lung cancer and proposed LRRC15 as a potential therapeutic target. LRRC15 deficiency suppressed lung cancer progression in mice by modulating macrophage polarization and enhancing CD8+ T-cell activation. Mechanistically, LRRC15 deficiency inhibited CD206+ macrophage polarization by reducing extracellular matrix (ECM) production in CAFs, leading to increased CD8+ T-cell cytotoxicity. Finally, development of a bispecific antibody targeting LRRC15 and TGFβ enabled effective downregulation of LRRC15 expression in CAFs and limited tumor progression in mice. This study highlights LRRC15 as a promising therapeutic target and provides insights into CAF-directed cancer treatment strategies. Significance: LRRC15 in cancer-associated fibroblasts enhances extracellular matrix deposition, facilitates M2 macrophage polarization, and suppresses CD8+ T cell–mediated immunity, thereby promoting lung cancer progression and representing a potential therapeutic target.
24 December 2025 in European Journal of Cancer
Neoadjuvant camrelizumab plus apatinib has shown a promising major pathological response (primary endpoint) and pathological complete response (a secondary endpoint) in patients with resectable stage IIA-IIIB non-small-cell lung cancer (NSCLC) in a previous single-arm phase 2 trial. Here, we present the 3-year survival outcomes and potential prognostic factors with extended follow-up. This single-arm phase 2 study enrolled patients with resectable stage IIA-IIIB NSCLC (stage IIIB, T3N2 only, according to the eighth edition of the American Joint Commission on Cancer TNM staging classification). Patients received three cycles of neoadjuvant camrelizumab (200 mg, intravenously, q2w) and apatinib (250 mg, orally, qd, for 5 days followed by 2 days off) followed by surgery. At 4-8 weeks after surgery, patients received either adjuvant camrelizumab monotherapy for up to 12 cycles or other strategies at the investigator's discretion. With the median follow-up of 42.6 months, the 3-year event-free survival (EFS), disease-free survival and overall survival were 58.9 % (95 % CI 46.9-69.1), 61.5 % (95 % CI 48.6-72.1), and 92.3 % (95 % CI 83.6-96.5), respectively. Among the pathological responses, residual viable tumors of ≤ 20 % were more strongly associated with improved EFS (HR 0.30, 95 % CI 0.13-0.72). Additionally, metabolic response on PET/CT after neoadjuvant treatment and ctDNA clearance during the perioperative period were significantly associated with improved EFS (HR 0.23 [95 % CI 0.08-0.62] and HR 0.23 [95 % CI 0.09-0.59], respectively). Neoadjuvant camrelizumab plus apatinib provides a potential sustained benefit for patients with resectable stage IIA-IIIB NSCLC. Metabolic response on PET/CT and perioperative ctDNA clearance might be potential biomarkers for predicting survival.